Abbott Laboratories (ABT) FY2024 results: revenue $42.0 billion, up 4.6% on the year
Abbott Laboratories (ABT) reported revenue of $42.0 billion for fiscal 2024, the year ended 31 December 2024, up 4.6% on the year before. Net income was $13.4 billion, up 134.2%, and diluted earnings per share $7.64. The figures are the company's own, from the 10-K it filed with the SEC on 21 February 2025.
Revenue
$42.0 billion
+4.6% on the year
FY2017FY2024
Operating margin
16.3%
16.2% a year earlier
FY2017FY2024
Net income
$13.4 billion
+134.2% on the year
FY2017FY2024
Diluted EPS
$7.64
+134.4% on the year
FY2017FY2024
this yearthe year beforeHover a bar for its figure.
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2024
FY2023
FY2022
On the year
Last 8 years
Operating cash flow
8,558
7,261
9,581
+17.9%
Capital expenditure
2,207
2,202
1,777
+0.2%
Free cash flow
6,351
5,059
7,804
+25.5%
Free cash flow margin
15.1%
12.6%
17.9%
Cash from investing
-2,338
-3,133
-1,740
Cash from financing
-5,404
-7,091
-7,636
Depreciation and amortisation
3,218
3,243
3,267
-0.8%
Share-based compensation
673
644
685
+4.5%
Buybacks
1,295
1,227
3,795
+5.5%
Dividends paid
3,836
3,556
3,309
+7.9%
Dividend per share
$2.24
$2.08
$1.92
+7.7%
Diluted shares, weighted
1,748m
1,749m
1,764m
-0.1%
Balance sheet
$ million
FY2024
FY2023
FY2022
On the year
Last 8 years
Shareholders' equity
47,664
38,603
36,686
+23.5%
Non-controlling interest
237
224
219
+5.8%
Debt
14,125
14,679
16,773
-3.8%
Operating lease liabilities
896
949
943
-5.6%
Other liabilities
18,492
18,759
19,817
-1.4%
Total liabilities and equity
81,414
73,214
74,438
+11.2%
Fixed assets
10,658
10,154
9,162
+5.0%
Goodwill
23,108
23,679
22,799
-2.4%
Intangible assets
6,647
8,815
10,454
-24.6%
Investments
1,237
1,182
1,054
+4.7%
Cash and equivalents
7,616
6,896
9,882
+10.4%
Receivables
6,925
6,565
6,218
+5.5%
Inventory
6,194
6,570
6,173
-5.7%
Other assets
19,029
9,353
8,696
+103.5%
Total assets
81,414
73,214
74,438
+11.2%
10-K for the year ended 31 December 2024, filed 21 February 2025: the filing.